ImmunityBio
IBRX
IBRX
39 hedge funds and large institutions have $6.57M invested in ImmunityBio in 2019 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 13 reducing their positions, and 14 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
57% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 14
75% less call options, than puts
Call options by funds: $13K | Put options by funds: $53K
Holders
39
Holding in Top 10
–
Calls
$13K
Puts
$53K
Top Buyers
| 1 | +$122K | |
| 2 | +$102K | |
| 3 | +$56.8K | |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$56.7K |
| 5 |
Bank of New York Mellon
New York
|
+$39K |
Top Sellers
| 1 | -$508K | |
| 2 | -$262K | |
| 3 | -$127K | |
| 4 |
Jane Street
New York
|
-$92K |
| 5 |
Goldman Sachs
New York
|
-$79K |